CDT Equity Inc. (NASDAQ:CDT) Sees Significant Growth in Short Interest

CDT Equity Inc. (NASDAQ:CDT) saw a large growth in short interest in May. As of May 29th, there was short interest totaling 53,538 shares, a growth of 70.8% from the May 14th total of 31,350 shares. Currently, 1.2% of the company’s stock are short sold. Based on an average daily volume of 5,554,158 shares, the short-interest ratio is presently 0.0 days.

CDT Equity Price Performance

Shares of CDT stock remained flat at $0.71 on Tuesday. 67,633 shares of the company were exchanged, compared to its average volume of 533,430. The stock has a market cap of $3.45 million, a P/E ratio of 0.00 and a beta of 1.44. The company’s fifty day moving average price is $2.22 and its 200 day moving average price is $19.28. CDT Equity has a 12-month low of $0.67 and a 12-month high of $610.00.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CDT Equity in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

CDT Equity Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.